Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy ...

The $13 billion figure shows the strength of the company’s railroad, energy and manufacturing, service, and retailing units.

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow ...

For most tech earnings, good wasn’t good enough. But it’s still possible to impress skeptical investors and flip a negative ...

The central bank has let the bond market do its heavy lifting when it comes to rates. But a cut is on the horizon if a weak ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I agree to the Terms of Use , Privacy Notice and Cookie ...

Take-Two reiterates fiscal 2027 guidance for net bookings even as ‘Grand Theft Auto VI’ preorders began June 25.

Wendy’s pulled its full-year outlook on Friday and cut its annual dividend, citing declining customer traffic and shrinking ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Dave lost 97% of its value before a 1-for-32 reverse split. Now the fintech stock has surged back. As SPACs mount a comeback, ...

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

Doximity stock surges, even after the medical networking and telehealth company’s earnings miss analysts’ targets.